Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Shares of Amgen Inc. AMGN advanced 1.99% to $319.10 Thursday, on what proved to be an all-around great trading session for ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Fintel reports that on September 27, 2024, Cantor Fitzgerald initiated coverage of Amgen (NasdaqGS:AMGN) with a Overweight ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...